GLP-1 obesity drugs set to become access battleground in lower-income countries
Published 3 d ago1 sourceEvidence: Reported
TLV reports 2025 pharmacy sales growth, with weight-loss medications as the primary driver. This signals sustained demand for GLP-1 class drugs in Sweden, though the report does not quantify the increase or specify which products. The trend matters for pharmaceutical market dynamics and healthcare spending in the Nordics.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 3 d ago1 sourceEvidence: Reported
Published 21 h ago1 sourceEvidence: Reported
Published 18 h ago1 sourceEvidence: Reported
Published 8 h ago1 sourceEvidence: Reported
Published 2 d ago3 sourcesEvidence: Reported
Published 13 h ago2 sourcesEvidence: Reported
Published 1 d ago22 sourcesEvidence: Reported
Published 2 d ago8 sourcesEvidence: Reported